Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cure Genetics Co. Ltd.

www.curegenetics.com

Latest From Cure Genetics Co. Ltd.

Venture Funding Deals: Orchard Brings Total To $291m

New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Cure Genetics Co. Ltd.
  • Senior Management
  • Yuanyuan Xu, CEO
  • Contact Info
  • Cure Genetics Co. Ltd.
    Phone: 512-6262-9259
    Shengwunami Pk 218 Xinghu St., Rm. 510
    Bldg. A4
    Suzhou, 215028
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register